What we are watching
Top 10 by severity and recency
MASH & NASH watchlist
Resmetirom opened MASH as a category. Akero, Viking, and 89bio Phase 3 readouts close the next window.
Madrigal’s resmetirom is the first FDA-approved MASH therapy — a category that did not commercially exist twelve months ago. Akero (efruxifermin), Viking (VK2809 and VK2735 cardiometabolic adjacency), and 89bio (pegozafermin) Phase 3 readouts will reshape adjacent cardiometabolic and cardiovascular positioning. The risk window between trial readout and equity repricing is narrow. AimwellBio tracks every Phase 2 and Phase 3 protocol amendment, biopsy endpoint, MAESTRO-NASH-style readout, and FDA correspondence in the indexer.
Saudi Arabia · Vision 2030
Saudi Arabia carries a structural diabetes-obesity burden. The Ministry of Health has positioned cardiometabolic disease as a Vision 2030 procurement priority.
SPIMACO Metabolic, Tabuk Metabolic, Julphar Metabolic, Hikma Metabolic, and Eva Pharma Metabolic anchor the GCC and MENA cardiometabolic supply surface. The cluster represents the highest-density sovereign-procurement opportunity for AimwellBio’s metabolic intelligence layer. SFDA approvals, MOH formulary movements, and cross-border GLP-1, GIP, and MASH infrastructure across Riyadh, Jeddah, Dubai, Abu Dhabi, Amman, and Cairo are already trackable through the indication-aware pipeline.
Decisions of this scale — coverage policy, capital procurement of GLP-1 supply, MASH access, and cardiometabolic prevention programs — cannot rest on a single vendor pipeline page. They require an adversarial verification layer with origin URLs, fetch timestamps, and reproducible claims for every signal.
Monitored issuers and operators
Volume & cadence of public disclosure
Methodology
This report is generated from a live ingest pipeline (tools/scout-ingest). Sources: FDA openFDA, ClinicalTrials.gov v2 API, PubMed E-utilities, SEC EDGAR, CMS Medicare Coverage Database, USPTO Patent Center, and manufacturer pipeline pages. Updated —. Every signal carries source URL and fetch timestamp; click any card to view origin.
Confidence framework. Source-backed > pattern-inferred > model-hypothesis > speculative. This report contains source-backed signals only. Pattern-inferred and model-hypothesis tiers are surfaced only inside member dashboards with explicit provenance flags.
Limitations. This is a public, ToS-compliant view. Closed-source manufacturer disclosures, ministry tenders, and private regulatory correspondence are out of scope for this surface. Members access an extended view with partner intelligence subject to NDA. Sovereign-tagged companies (KSA, GCC, MENA) reflect publicly observable regional headquarters; ministry-procurement detail is reserved for the partner intelligence surface.